Opportunity Information: Apply for PA 16 086
Apply for PA 16 086
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394, 93.395, 93.397.
- This funding opportunity was created on Jan 20, 2016 and posted on Jan 20, 2016.
- Applicants must submit their applications by Apr 15, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $100,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp)" (Funding Opportunity Number PA 16-086) is a National Cancer Institute (NCI) initiative, run through its Center for Global Health (CGH), aimed at strengthening clinical research focused on pediatric Burkitt Lymphoma (BL) in low- and middle-income countries (LMICs). The central idea is to reduce the burden of this fast-growing childhood cancer in settings where resources, specialized diagnostics, and treatment infrastructure can be limited, by building practical, on-the-ground collaborations between well-established U.S. cancer research centers and partner institutions in LMICs.
This funding is offered as an administrative supplement, meaning it is not a standalone grant for new applicants. Instead, the NCI intends to add targeted funds onto existing P30 NCI-designated Cancer Center Support Grants. In practice, this structure is meant to leverage the expertise, research capacity, and administrative systems already supported through NCI-designated Cancer Centers, while directing those strengths toward pilot clinical research projects that address real care and research gaps for pediatric BL in LMIC partner sites. The work supported is described as pilot in nature, with an expectation that these smaller, focused projects will help generate evidence, refine approaches, and build the clinical research foundation needed to improve BL treatment strategies in the region.
A major emphasis of the opportunity is partnership and collaboration. The NCI is explicitly encouraging research relationships between NCI-designated Cancer Centers and institutions based in LMICs, with the expectation that these partnerships will lead to measurable improvements in diagnosis and treatment approaches for children with BL. Although the announcement text is brief, the intent is clear: these supplements should help address clinical research needs tied to treating BL in LMIC contexts, which commonly includes challenges like diagnostic accuracy, staging and risk stratification, treatment delivery and supportive care, toxicity management, and feasible protocol adaptations that fit local realities while still improving outcomes.
From an administrative standpoint, the opportunity is classified as a discretionary grant under health and education activity categories, and it is associated with CFDA numbers 93.394, 93.395, and 93.397. The maximum award amount listed is $100,000. The opportunity was posted and created on January 20, 2016, with an application closing date of April 15, 2016. While the eligibility list in the source data includes many organization types (government entities, higher education institutions, nonprofits, and for-profit organizations), the key limiting factor in the description is that awards are administrative supplements to currently funded P30 NCI-designated Cancer Center grants, so the practical applicant pool is centered on those funded NCI-designated Cancer Centers seeking to extend their existing award to support an LMIC-focused pediatric BL pilot project.
Overall, this FOA is designed to catalyze early-stage, clinically relevant research on pediatric Burkitt Lymphoma where the disease burden is significant, by funding small, targeted pilot efforts that are embedded in cross-institution collaborations. The expected outcome is better-informed and more effective diagnosis and treatment strategies tailored to LMIC settings, along with stronger clinical research partnerships capable of sustaining progress beyond the initial pilot work.
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PA 16-086.
Which agency is offering this opportunity?
This is a National Cancer Institute (NCI) initiative, run through NCI's Center for Global Health (CGH).
What is the main goal of this funding opportunity?
The goal is to strengthen clinical research focused on pediatric Burkitt Lymphoma (BL) in low- and middle-income countries (LMICs). The intent is to help reduce the burden of this fast-growing childhood cancer by supporting practical, on-the-ground collaborations that can improve diagnosis and treatment approaches in resource-limited settings.
What disease area does the opportunity focus on?
The focus is pediatric Burkitt Lymphoma (BL), a fast-growing childhood cancer, specifically in LMIC settings.
What is meant by "administrative supplement" in this announcement?
An administrative supplement is not a standalone grant for brand-new applicants. Instead, NCI adds targeted funds onto an existing, currently funded grant. In this case, the supplement is intended to be added to existing P30 NCI-designated Cancer Center Support Grants.
Is this a standalone funding opportunity for new applicants?
No. This opportunity is designed as an administrative supplement, which means it is tied to an existing eligible award rather than supporting entirely new, independent applications.
What existing grant mechanism must be in place to apply for this supplement?
The supplement is intended to be added to currently funded P30 NCI-designated Cancer Center Support Grants (Cancer Center Support Grants).
Who is the practical target applicant group for this funding?
While general eligibility lists may include many organization types, the practical applicant pool is centered on currently funded NCI-designated Cancer Centers that have P30 awards and want to extend those awards with an LMIC-focused pediatric BL pilot clinical research project.
What role do low- and middle-income countries (LMICs) play in the project?
LMICs are the intended settings for the clinical research focus and partnership. The funding is meant to support work conducted through collaborations between U.S. NCI-designated Cancer Centers and partner institutions based in LMICs, addressing clinical research needs and care realities in those countries.
What kind of collaboration does NCI encourage under this opportunity?
NCI explicitly encourages research relationships between well-established U.S. cancer research centers (NCI-designated Cancer Centers) and institutions in LMICs, with the expectation that these partnerships will lead to measurable improvements in diagnosis and treatment approaches for children with BL.
What types of projects are expected to be supported?
The supported work is described as pilot in nature. The expectation is that smaller, focused pilot clinical research projects will generate evidence, refine approaches, and build a foundation for improved BL treatment strategies in LMIC partner sites.
Is the supported work intended to be pilot or large-scale?
The announcement describes the work as pilot in nature, suggesting targeted, early-stage efforts rather than large-scale, long-term programs.
What kinds of clinical research gaps does the FOA aim to address?
The description emphasizes real care and research gaps for pediatric BL in LMIC settings. Examples of commonly cited needs in this context include diagnostic accuracy, staging and risk stratification, treatment delivery and supportive care, toxicity management, and feasible protocol adaptations that fit local realities while improving outcomes.
Why does the FOA emphasize leveraging NCI-designated Cancer Centers?
The supplement structure is meant to leverage the expertise, research capacity, and administrative systems already supported through NCI-designated Cancer Centers, and then direct those strengths toward LMIC-focused pediatric BL pilot clinical research projects.
What is the maximum award amount for this opportunity?
The maximum award amount listed is $100,000.
How is this opportunity classified from an administrative standpoint?
It is classified as a discretionary grant under health and education activity categories.
Which CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.394, 93.395, and 93.397.
When was this opportunity posted and created?
The opportunity was posted and created on January 20, 2016.
What is the application closing date?
The application closing date listed is April 15, 2016.
Does the opportunity description indicate what outcomes NCI expects?
Yes. The FOA is designed to catalyze early-stage, clinically relevant research that supports better-informed and more effective diagnosis and treatment strategies tailored to LMIC settings, while also strengthening cross-institution clinical research partnerships that can sustain progress beyond the pilot period.
What is the overarching rationale for focusing on pediatric BL in LMICs?
The rationale described is that pediatric BL can represent a significant burden in LMIC settings, where resources, specialized diagnostics, and treatment infrastructure may be limited. The FOA aims to improve practical clinical research and collaborations to address those constraints.
Does the FOA specify that measurable improvements are expected?
Yes. The opportunity states an expectation that partnerships and the supported work will lead to measurable improvements in diagnosis and treatment approaches for children with BL.
Is this opportunity primarily about building partnerships or funding treatment directly?
Based on the description, the funding is aimed at strengthening clinical research and building practical collaborations between U.S. NCI-designated Cancer Centers and LMIC institutions, with the downstream aim of improving diagnosis and treatment approaches.
What makes this opportunity different from a typical research grant competition?
This opportunity is not positioned as an open competition for new standalone awards. It is an administrative supplement that adds targeted funds to existing P30 Cancer Center Support Grants, focusing those established centers' capabilities on pilot clinical research for pediatric BL in LMIC partner sites.
Browse more opportunities from the same category: Education, Health
Next opportunity: Sustainable WASH Systems BAA
Previous opportunity: Surveillance, Service Data Analysis and Capacity Building to Support Management, Leadership and Sustainability of HIV Programs in Haiti and other Health Initiative under the President’s Emergency Plan for AIDS Relief (PEPFAR)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 086
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 086) also looked into and applied for these:
| Funding Opportunity |
|---|
| Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 16 089 Funding Number: PAR 16 089 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 16 008 Funding Number: RFA CA 16 008 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01) Apply for PAR 16 105 Funding Number: PAR 16 105 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $400,000 |
| Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03) Apply for RFA DA 16 015 Funding Number: RFA DA 16 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01) Apply for PAR 16 111 Funding Number: PAR 16 111 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Increased Knowledge and Innovative Strategies to Reduce HIV Incidence-iKnow Projects (R01) Apply for PAR 16 117 Funding Number: PAR 16 117 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21) Apply for PAR 16 123 Funding Number: PAR 16 123 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3) Apply for RFA DA 17 015 Funding Number: RFA DA 17 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01) Apply for PAR 16 122 Funding Number: PAR 16 122 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| The Application of Big Data Analytics to Drug Abuse Research (R01) Apply for PA 16 119 Funding Number: PA 16 119 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Emerging Questions in Cancer Systems Biology (U01) Apply for PAR 16 131 Funding Number: PAR 16 131 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program to Promote Diversity - Research Experiences (R25) Apply for PAR 16 138 Funding Number: PAR 16 138 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| The Early Detection Research Network: Biomarker Developmental Laboratories (U01) Apply for RFA CA 16 009 Funding Number: RFA CA 16 009 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Coordinating Center for Barrett's Esophagus Translational Research Network (BETRNet)(U24) Apply for RFA CA 16 007 Funding Number: RFA CA 16 007 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $250,000 |
| Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25) Apply for PAR 16 139 Funding Number: PAR 16 139 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Research Centers for Barretts Esophagus Translational Research Network (BETRNet)(U54) Apply for RFA CA 16 006 Funding Number: RFA CA 16 006 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $900,000 |
| Population Health Interventions: Integrating Individual and Group Level Evidence (R21) Apply for PA 16 147 Funding Number: PA 16 147 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Role of Astrocytes and Astrocytic Networks in Drug Abuse (R21) Apply for PA 16 145 Funding Number: PA 16 145 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Population Health Interventions: Integrating Individual and Group Level Evidence (R01) Apply for PA 16 146 Funding Number: PA 16 146 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Role of Astrocytes and Astrocytic Networks in Drug Abuse (R01) Apply for PA 16 144 Funding Number: PA 16 144 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 086", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.